At a glance
ClinicalIndex Comparison RecordN/ACompleted· 2,500 enrolled
Drug / intervention
Maraviroc along with an optimized background antiretroviral drug regimen +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
AN INTERNATIONAL, MULTICENTER, PROSPECTIVE OBSERVATIONAL STUDY OF THE SAFETY OF MARAVIROC USED WITH OPTIMIZED BACKGROUND THERAPY IN TREATMENT-EXPERIENCED HIV-1 INFECTED PATIENTS
In Brief
An observational study evaluating Maraviroc along with an optimized background antiretroviral drug regimen and Optimized background antiretroviral drug regimen without maraviroc for Human Immunodeficiency Virus. Completed, enrolled 2,500 participants across 269 sites in 11 countries.
Detailed Summary
The study will assess if use of maraviroc along with an optimized background regimen of antiretroviral drugs in usual clinical practice is as safe as using only an optimized regimen of antiretroviral drugs.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHuman Immunodeficiency Virus
CountriesBelgium, Brazil, Canada, France, Germany, Greece, Italy, Puerto Rico, Spain, United Kingdom, United States
CollaboratorsPfizer
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2008
First PostedApr 2008
Primary CompletionFeb 2019
TodayJul 2026
First PostedApr 24, 2008
Enrollment StartMar 31, 2008
Primary CompletionFeb 14, 2019
TodayJul 2, 2026
Enrollment to primary: 10.9 yearsPosted 18.2 years ago
Interventions
Maraviroc along with an optimized background antiretroviral drug regimendrug
Maraviroc prescribed per approved local label.
Optimized background antiretroviral drug regimen without maravirocdrug
Optimized background antiretroviral therapy prescribed per approved local label and treatment guidelines.